Xvivo Perfusion AB (publ)

BATS-CHIXE:XVIVOS Stock Report

Market Cap: SEK 10.1b

Xvivo Perfusion Valuation

Is XVIVOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XVIVOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
SEK 439.34
Fair Value
27.0% undervalued intrinsic discount
6
Number of Analysts

Below Fair Value: XVIVOS (SEK320.6) is trading below our estimate of fair value (SEK439.34)

Significantly Below Fair Value: XVIVOS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XVIVOS?

Key metric: As XVIVOS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for XVIVOS. This is calculated by dividing XVIVOS's market cap by their current earnings.
What is XVIVOS's PE Ratio?
PE Ratio73.9x
EarningsSEK 137.00m
Market CapSEK 10.12b

Price to Earnings Ratio vs Peers

How does XVIVOS's PE Ratio compare to its peers?

The above table shows the PE ratio for XVIVOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.2x
AMS Advanced Medical Solutions Group
59.7x39.17%UK£423.2m
TSTL Tristel
30.3x19.05%UK£186.1m
CTEC ConvaTec Group
39.6x16.92%UK£5.6b
CRW Craneware
67.3x24.09%UK£745.9m
XVIVOS Xvivo Perfusion
73.9x48.09%SEK 10.1b

Price-To-Earnings vs Peers: XVIVOS is expensive based on its Price-To-Earnings Ratio (73.9x) compared to the peer average (49.6x).

Price to Earnings Ratio vs Industry

How does XVIVOS's PE Ratio compare vs other companies in the European Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies12PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: XVIVOS is expensive based on its Price-To-Earnings Ratio (73.9x) compared to the European Medical Equipment industry average (32x).

Price to Earnings Ratio vs Fair Ratio

What is XVIVOS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XVIVOS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio73.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate XVIVOS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XVIVOS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
SEK 448.50
0%
14.02%SEK 520.00SEK 335.00n/a6
May ’26SEK 317.20
SEK 448.50
+41.39%
14.02%SEK 520.00SEK 335.00n/a6
Apr ’26SEK 317.50
SEK 476.17
+49.97%
17.05%SEK 567.00SEK 325.00n/a6
Mar ’26n/a
SEK 518.67
0%
8.84%SEK 567.00SEK 460.00n/a6
Feb ’26n/a
SEK 522.00
0%
8.06%SEK 567.00SEK 480.00n/a6
Jan ’26n/a
SEK 538.17
0%
7.79%SEK 584.00SEK 480.00n/a6
Dec ’25n/a
SEK 538.17
0%
7.79%SEK 584.00SEK 480.00n/a6
Nov ’25n/a
SEK 545.67
0%
6.26%SEK 584.00SEK 480.00n/a6
Oct ’25n/a
SEK 549.00
0%
6.57%SEK 584.00SEK 480.00n/a6
Sep ’25n/a
SEK 549.00
0%
6.57%SEK 584.00SEK 480.00n/a6
Aug ’25n/a
SEK 549.00
0%
6.57%SEK 584.00SEK 480.00n/a6
Jul ’25SEK 415.50
SEK 440.00
+5.90%
13.89%SEK 520.00SEK 340.00n/a6
Jun ’25SEK 430.00
SEK 408.00
-5.12%
12.02%SEK 468.00SEK 340.00n/a6
May ’25SEK 359.00
SEK 408.00
+13.65%
12.02%SEK 468.00SEK 340.00SEK 317.206
Apr ’25SEK 273.00
SEK 382.60
+40.15%
9.01%SEK 425.00SEK 340.00SEK 317.505
Mar ’25n/a
SEK 382.60
0%
9.01%SEK 425.00SEK 340.00n/a5
Feb ’25SEK 303.00
SEK 389.60
+28.58%
7.81%SEK 425.00SEK 340.00n/a5
Jan ’25SEK 329.25
SEK 377.00
+14.50%
16.34%SEK 450.00SEK 280.00n/a5
Dec ’24n/a
SEK 363.75
0%
17.10%SEK 450.00SEK 280.00n/a4
Nov ’24n/a
SEK 371.67
0%
18.84%SEK 450.00SEK 280.00n/a3
Oct ’24n/a
SEK 391.67
0%
11.53%SEK 450.00SEK 340.00n/a3
Sep ’24n/a
SEK 391.67
0%
11.53%SEK 450.00SEK 340.00n/a3
Aug ’24n/a
SEK 376.67
0%
7.22%SEK 405.00SEK 340.00n/a3
Jul ’24n/a
SEK 376.67
0%
7.22%SEK 405.00SEK 340.00SEK 415.503
Jun ’24n/a
SEK 376.67
0%
7.22%SEK 405.00SEK 340.00SEK 430.003
May ’24SEK 281.50
SEK 370.00
+31.44%
7.24%SEK 405.00SEK 340.00SEK 359.003
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
SEK 447.38
Fair Value
28.3% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 11:01
End of Day Share Price 2025/05/12 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xvivo Perfusion AB (publ) is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
Maria Vara FernándezBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB